Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >


HoustonTX
Posted on: Feb 2 2019, 01:44 PM


Group: Member
Posts: 5

Click on "See Visitor's Posts" on the home page:

https://www.facebook.com/JoeRoganEXP/

You also have to be logged into Facebook, I think.

If I get any responses from the Joe Rogan Experience, I will definitely pass that along.
  Forum: By Share Code

HoustonTX
Posted on: Feb 2 2019, 12:17 PM


Group: Member
Posts: 5

I just posted this on the Joe Rogan Experience Podcast Facebook page:

Hey Joe, someone mentioned that you brought up Vitiligo on a recent podcast. You might be interested in a new drug on the cusp of approval in the US called Scenesse. It's a melanocortin anti-inflammatory drug for treating a number of skin conditions.

The current application would approve the drug for a rare disease, EPP (Poryphia). But, it's also been shown to treat Vitiligo, and their plan is to follow up with approval for that indication afterwards.

More information can be found on their website at:

https://www.clinuvel.com

The drug is already approved in the EU for EPP.
  Forum: By Share Code

HoustonTX
Posted on: Sep 20 2017, 12:16 AM


Group: Member
Posts: 5

I read the release a number of times, and I agree it is ambiguous. It is not clear if they indicate that they'll have the last module of the NDA application submitted by December 2017, or just the safety data. Or, perhaps the safety data is the last module?

In any case, it sounds positive that a REMS protocol will not be required and that Clinuvel can instead mirror what it has already been doing in Europe with respect to PASS.

Looking forward to December and confirmation on timing.
  Forum: By Share Code

HoustonTX
Posted on: Jun 28 2017, 12:15 AM


Group: Member
Posts: 5

I like your optimism, but I just read a June 2017 interview with Lachlan Hay where he indicated that the FDA NDA would not be filed in the first half of 2017, but hopefully by the end of the year. That being the case, I imagine an FDA decision will not be forthcoming any time soon.
  Forum: By Share Code

HoustonTX
Posted on: Feb 11 2016, 08:05 AM


Group: Member
Posts: 5

My German is pretty rusty, so I ran the article through Google's translator. So, FWIW, the article appears to discuss Florian Hamm's earlier legal troubles, his new outlook on life and his thoughts on current investments. He goes on to say there are a multitude of businesses that are candidates to short, but he characterizes Clinuvel as a long-term investment.
  Forum: By Share Code


Cant find what you are looking for? Show all active topics from the last 3 months


New Posts  New Replies
No New Posts  No New Replies
Hot topic  Hot Topic (New)
No new  Hot Topic (No New)



TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING